Electroducer has announced that it has raised €3 million (US$3.65M) from private investors and French public stakeholders which will be used for marketing its new technology—the Electroducer Sleeve. The device is based on a technique called direct wire pacing (DWP) and is used to treat heart valve disease.
Results of a study of the devicewere presented at EuroPCR 2021 (18–20 May, virtual). The device replaces the need for cardiac stimulation using a temporary pacing catheter, instead providing this stimulation via the guidewire connected to an external pacemaker. The purpose of the Electroducer Sleeve is to simplify, enhance and expand the use of DWP, Electroducer said in a press release, using a turnkey method with proven clinical benefits.
Initially, the Electroducer Sleeve device will be used for aortic valve replacement procedures and for more complex coronary procedures treating the narrowing of the arteries that supply the heart. Subsequently, the technology will also be applied to procedures involving the mitral and tricuspid heart valves.
Benjamin Faurie, chairman, chief executive officer and founder of Electroducer, said: “I am proud to see the technique that I established ten years ago is now widespread in France and is continuing to be developed through a new medical device that is 100% safe and effective for the patient. Initial reports are very promising and indicate a shallow learning curve, as the solution is universal and needs no other special equipment. We are very much looking forward to receiving marketing authorisation, which will allow the technique to be rolled out worldwide and save a lot of lives.”
The Electroducer Sleeve is expected to come onto the market in the USA and Europe during 2022, following US Food and Drug Administration (FDA) authorisation and CE marking in Europe.
